WO2001026737A3 - Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator - Google Patents

Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator Download PDF

Info

Publication number
WO2001026737A3
WO2001026737A3 PCT/EP2000/009883 EP0009883W WO0126737A3 WO 2001026737 A3 WO2001026737 A3 WO 2001026737A3 EP 0009883 W EP0009883 W EP 0009883W WO 0126737 A3 WO0126737 A3 WO 0126737A3
Authority
WO
WIPO (PCT)
Prior art keywords
activator
treatment
assay
identifying
cartilage loss
Prior art date
Application number
PCT/EP2000/009883
Other languages
French (fr)
Other versions
WO2001026737A2 (en
Inventor
Thomas Meyer
Michaela Kneissel
Brigitte Fournier
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Thomas Meyer
Michaela Kneissel
Brigitte Fournier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, Thomas Meyer, Michaela Kneissel, Brigitte Fournier filed Critical Novartis Ag
Priority to EP00972703A priority Critical patent/EP1239922A2/en
Priority to JP2001529798A priority patent/JP2003511426A/en
Priority to AU11346/01A priority patent/AU1134601A/en
Publication of WO2001026737A2 publication Critical patent/WO2001026737A2/en
Publication of WO2001026737A3 publication Critical patent/WO2001026737A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method for the identification of a compound having bone growth promoting activity comprising contacting a test compound with a biological system which comprises a functional RORα receptor and which is capable of generating a detectable signal in response to activation of the RORα receptor by a compound having bone growth promoting activity, and monitoring the system for the generation of the signal and the use of such compounds for the prophylaxis or treatment of diseases or medical conditions which involve excessive bone or cartilage loss.
PCT/EP2000/009883 1999-10-11 2000-10-09 Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator WO2001026737A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00972703A EP1239922A2 (en) 1999-10-11 2000-10-09 Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator
JP2001529798A JP2003511426A (en) 1999-10-11 2000-10-09 Assay method
AU11346/01A AU1134601A (en) 1999-10-11 2000-10-09 Assay method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9924057.4 1999-10-11
GBGB9924057.4A GB9924057D0 (en) 1999-10-11 1999-10-11 Organic compounds

Publications (2)

Publication Number Publication Date
WO2001026737A2 WO2001026737A2 (en) 2001-04-19
WO2001026737A3 true WO2001026737A3 (en) 2001-10-18

Family

ID=10862542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009883 WO2001026737A2 (en) 1999-10-11 2000-10-09 Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator

Country Status (5)

Country Link
EP (1) EP1239922A2 (en)
JP (1) JP2003511426A (en)
AU (1) AU1134601A (en)
GB (1) GB9924057D0 (en)
WO (1) WO2001026737A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE392432T1 (en) * 2001-05-07 2008-05-15 Centre Nat Rech Scient FRAGMENTS OF RETINOIC ACID-RELATED ORPHAN RECEPTORS (ROR) CONTAINING THE LIGAND BINDING DOMAIN (LBD), CRYSTAL STRUCTURE OF THE LBD OF ROR-BETA AND THEIR USES
US20050165218A1 (en) * 2002-04-29 2005-07-28 Rene Beerli Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
WO2004047855A2 (en) * 2002-11-27 2004-06-10 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0552612A2 (en) * 1992-01-22 1993-07-28 F. Hoffmann-La Roche Ag Methods for determining and isolating compounds which bind directly to nucleosolic proteins
US5854277A (en) * 1994-11-15 1998-12-29 Bayer Corporation Thiophenebutanoic acid derivatives as matrix metalloprotease inhibitors
FR2776388A1 (en) * 1998-03-20 1999-09-24 Lipha Screening assay for substances having anti-atherosclerotic activity
US5958683A (en) * 1994-03-30 1999-09-28 Novartis Corporation Screening method using the RZR receptor family

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0552612A2 (en) * 1992-01-22 1993-07-28 F. Hoffmann-La Roche Ag Methods for determining and isolating compounds which bind directly to nucleosolic proteins
US5958683A (en) * 1994-03-30 1999-09-28 Novartis Corporation Screening method using the RZR receptor family
US5854277A (en) * 1994-11-15 1998-12-29 Bayer Corporation Thiophenebutanoic acid derivatives as matrix metalloprotease inhibitors
FR2776388A1 (en) * 1998-03-20 1999-09-24 Lipha Screening assay for substances having anti-atherosclerotic activity

Also Published As

Publication number Publication date
GB9924057D0 (en) 1999-12-15
WO2001026737A2 (en) 2001-04-19
EP1239922A2 (en) 2002-09-18
JP2003511426A (en) 2003-03-25
AU1134601A (en) 2001-04-23

Similar Documents

Publication Publication Date Title
ATE278801T1 (en) DETECTION OF BIOLOGICAL MOLECULES USING CHEMICAL AMPLIFICATION AND OPTICAL SENSOR
WO2005034722A3 (en) Bone fixation systems
DE69231421D1 (en) FIBRINE OR FIBRINOGEN AND BIODEGRADABLE AND BIOCOMPATIBLE POLYMERS CONTAINING COMPOSITION FOR TISSUE TREATMENT
ES2092107T3 (en) IMPLANT CHECK.
DE60303758D1 (en) Blood glucose monitoring system using an implantable medical device
ATE288723T1 (en) DEVICE FOR FIXING OSTEOPOROTIC BONE
ATE205602T1 (en) METHOD AND DEVICE FOR DETECTING AND QUANTIFYING GLUCOSE IN BODY FLUID
ATE535199T1 (en) FLUID AND DEVICES FOR REDUCING THE MINERAL CONTENT OF CALCIFIED VASCULAR LESIONS
DE69232490D1 (en) DEVICE FOR TISSUE EXAMINATION USING ULTRASONIC CONTRASTING AGENTS
DE59410356D1 (en) DEVICE FOR THERMAL DEODILATION OF BIOLOGICAL TISSUE
FI863135A (en) EN PROTES SOM FAESTER BAETTRE VID BEN.
SE9103332D0 (en) METHOD FOR THE DIAGNOSIS OF BLOOD COAGULATION DESORDERS
DE69618482D1 (en) DEVICE FOR CONTROLLING PROSTHESIS AND OTHER AUXILIARIES
GB9924957D0 (en) Novel treatment
WO2001026737A3 (en) Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator
DE69739317D1 (en) PREVIOUS IDENTIFICATION OF LYSOSOMAL STORAGE DISEASE
ES2078733T3 (en) METHOD FOR THE DETECTION OF ANTI-RNA ANTIBODIES.
WO2000012047A3 (en) Enhancement of return to independent living status with a growth hormone secretagogue
DE60037676D1 (en) METHOD FOR DIAGNOSIS OF RICKETTSIA PULICIS
ES2093277T3 (en) METHOD FOR THE DETECTION OF GASTRIC EPITHELIAL DAMAGE.
FR2721714B1 (en) Device for evaluating the blood coagulant activity of a biological sample, disposable after single use, and method of implementation.
AU3241889A (en) Reagent system for immunologically assaying complex of human plasminogen activator inhibitor and human tissue plasminogen activator, and assay kit therefor
ES2099876T3 (en) PROCEDURE FOR THE DETERMINATION OF ANTICOAGULANT LUPUS ANTIBODIES THAT CAUSE THROMBOSIS.
DK0790245T3 (en) Substituted thiophenylalkenyl carboxylic acid guanides, process for their preparation, their use as a drug or diagnostic, and drug containing them
AU1726495A (en) Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000972703

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10110144

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 529798

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000972703

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000972703

Country of ref document: EP